SCHEMBL353132

SCHEMBL353132

CNC(=O)CCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 1/20 0.68
HDAC8 Q9BY41 1/20 0.68
HDAC6 Q9UBN7 1/20 0.68
HDAC1 Q13547 3/20 0.63
MAPT P10636 2/20 0.63
HTT P42858 1/20 0.63
ALDH1A1 P00352 3/20 0.61
KEAP1 Q14145 1/20 0.59
KDM4E B2RXH2 1/20 0.59
RECQL P46063 1/20 0.59
GAA P10253 1/20 0.58
HPGD P15428 1/20 0.57
TSHR P16473 1/20 0.56
FFAR1 O14842 2/20 0.56
HDAC3 O15379 1/20 0.56
P2RX7 Q99572 1/20 0.56
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
KMT2A Q03164 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30916851 0.98 HDAC2 (0.66) HDAC2HDAC8HDAC6HDAC1MAPT
SCHEMBL10094799 0.96 HDAC1 (0.70) HDAC2HDAC8HDAC6HDAC1MAPT
SCHEMBL14387746 0.89 HDAC1 (0.53) HDAC2HDAC8HDAC6HDAC1MAPT
SCHEMBL622139 0.88 HDAC1 (0.70) HDAC2HDAC8HDAC6HDAC1MAPT
SCHEMBL16360065 0.87 HPGD (0.58) HDAC2HDAC8HDAC6HDAC1MAPT
SCHEMBL6630702 0.86 HDAC1 (0.69) HDAC2HDAC8HDAC6HDAC1MAPT
SCHEMBL5990328 0.85 HDAC1 (0.72) HDAC2HDAC8HDAC6HDAC1MAPT
SCHEMBL8009605 0.85 HDAC1 (0.72) HDAC2HDAC8HDAC6HDAC1MAPT
SCHEMBL16658763 0.85 HDAC1 (0.72) HDAC2HDAC8HDAC6HDAC1MAPT
SCHEMBL16658762 0.85 HDAC1 (0.72) HDAC2HDAC8HDAC6HDAC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116217414-A Preparation method of N-methyl-3-hydroxyamphetamine 山东新时代药业有限公司 2023-06-06 CN claimed
US-10626438-B2 Fluorescent substrates for determining lysine modifying enzyme activity THE BROAD INSTITUTE, INC. (US) 2020-04-21 US claimed
CN-108752241-A Acyl group guanidine for treating arthropathy 默克专利股份公司 2018-11-06 CN claimed
US-20180155760-A1 FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY BROAD INST INC (US) 2018-06-07 US claimed
US-9856509-B2 Fluorescent substrates for determining lysine modifying enzyme activity THE BROAD INSTITUTE, INC. (US) 2018-01-02 US claimed
EP-3008055-B1 TETRAZOLONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2017-07-19 EP claimed
EP-2661436-B1 NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2016-04-13 EP claimed
US-9198426-B2 Use of 5 pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-12-01 US claimed
US-20140335550-A1 FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY THE BROAD INSTITUTE, INC. (US) 2014-11-13 US claimed
EP-2773653-A1 FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY The Broad Institute, Inc. (US) 2014-09-10 EP claimed
EP-1465869-A4 MODULATORS OF LXR X CEPTOR THERAPEUTICS INC (US) 2005-12-28 EP claimed
JP-2005536450-A 2005-12-02 JP claimed
WO-2005110399-A2 ZINC-BINDING GROUPS FOR METALLOPROTEIN INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-11-24 WO claimed
CN-1678534-A Synergistic biocidal mixtures HERCULES INC (US) 2005-10-05 CN claimed
WO-2005044810-A1 GLYT2 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-05-19 WO claimed
EP-1465869-A1 MODULATORS OF LXR X-Ceptor Therapeutics, Inc. (US) 2004-10-13 EP claimed
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS, INC. 2003-09-25 US claimed
WO-2003059884-A1 MODULATORS OF LXR X-CEPTOR THERAPEUTICS, INC. (US) 2003-07-24 WO claimed
EP-0923539-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1999-06-23 EP claimed
WO-1998003473-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-01-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors NR1H2, NR1H3, NCOA1 HDAC2 918/4885HDAC8 368/4885HDAC6 2666/4885
US-20180155760-A1 FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY KDM1A, MAN2B1, KDM3A HDAC2 390/4885HDAC8 1711/4885HDAC6 1421/4885
US-10626438-B2 Fluorescent substrates for determining lysine modifying enzyme activity KDM1A, MAN2B1, KDM3A HDAC2 390/4885HDAC8 1711/4885HDAC6 1421/4885
US-20140335550-A1 FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY MAN2B1, KDM1A, KDM3A HDAC2 624/4885HDAC8 1970/4885HDAC6 1712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.